Influence of age on the clinical outcomes of coronary revascularisation for the treatment of patients with multivessel de novo coronary artery lesions: sirolimus-eluting stent vs. coronary artery bypass surgery and bare metal stent, insight from the multicentre randomised Arterial Revascularisation Therapy Study Part I (ARTS-I) and Part II (ARTS-II)

被引:8
|
作者
Legrand, Victor M. [2 ]
Garg, Scot [1 ]
Serruys, Patrick W. [1 ]
Virtanen, Kari S. [3 ]
Szurawitzki, Guenter [4 ]
Voudris, Vassilis [5 ]
Fontanelli, Alessandro [6 ]
Endersen, Knut [7 ]
Kranjec, Igor [8 ]
Rademaker, Tessa [9 ]
Stefanidis, Christodoulos I. [10 ]
Wittebols, Kristel [11 ]
机构
[1] Erasmus MC, Thoraxctr, NL-3015 GD Rotterdam, Netherlands
[2] CHU Sart Tilman, B-4000 Liege, Belgium
[3] Univ Helsinki, Cent Hosp, Helsinki, Finland
[4] Elisabeth Hosp, Essen, Germany
[5] Onassis Cardiac Surg Ctr, Athens, Greece
[6] San Bortolo Hosp, Vicenza, Italy
[7] Riskhosp, Oslo, Norway
[8] Clin Ctr Ljubljana, Ljubljana, Slovenia
[9] Cardialysis BV, Rotterdam, Netherlands
[10] Hippokrateion Hosp, Athens, Greece
[11] Johnson & Johnson Co, Cordis, Waterloo, Belgium
关键词
Ageing; coronary artery disease; revascularisation; bare metal stents; sirolimus-eluting stents; surgery; GREATER-THAN-OR-EQUAL-TO-80; YEARS; DIABETES-MELLITUS; ELDERLY-PATIENTS; CARDIAC-SURGERY; FOLLOW-UP; INTERVENTION; DISEASE; MORTALITY; EUROSCORE; STRATEGY;
D O I
10.4244/EIJV6I7A144
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: We sought to evaluate the prognostic impact of age on the procedural results and subsequent clinical outcomes in patients with multivessel disease (MVD) treated either by coronary artery bypass surgery (CABG) or by percutaneous coronary intervention (PCI) with or without drug eluting stents, based on data of the Arterial Revascularisation Therapies Study (ARTS) part land part II. The potential influence of age in determining the most appropriate revascularisation strategy for patients with MVD is largely unknown. Methods and results: Three year clinical outcome of ARTS I patients randomised to PCI with bare metal stent (BMS) (n= 600) or CABG (n= 605), and matched patients treated by PCI with sirolimus-eluting stents (SES) in ARTS II (n= 607) were reviewed according to four age quartiles. Endpoints were measured in terms of major adverse cardiac and cerebrovascular events MACCE) during hospital stay and up to three years. The frequency of female, diabetes, hypertension, peripheral vascular disease, pulmonary disease, as well as lesion complexity increased with age. At three years, MACCE free survival was comparable between patients treated by CABG or SES PCI, regardless of age quartile. The incidence of MACCE was higher among ARTS I BMS treated patients in all but the second age quartile. This was primarily related to a higher need for repeat revascularisation among BMS treated patients. However, age, which emerged as a strong independent predictor of MACCE following CABG (p<0.005), was not predictive of adverse events following PCI. Conversely, diabetes was the strongest independent predictor of MACCE among PCI treated patients (p<0.02), but didn't affect three-year outcomes following CABG. Conclusions: Age seems to influence the CABG outcome in-hospital but not PCI. PCI-SES could offer lower immediate risk in patients with MVD and comparable long-term outcome as CABG especially in older patients. The worst outcome of PCI-BMS group is primarily related to the need for repeat revascularisation. Diabetes is the most important predictor of MACCE following PCI.
引用
收藏
页码:838 / 845
页数:8
相关论文
共 27 条
  • [1] Arterial revascularization therapies study part II of the Sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions
    Serruys, PW
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (03) : 7A - 7A
  • [2] Sirolimus-eluting stent versus coronary artery bypass grafting and bare metal stent for the treatment of multivessel coronary artery disease including involvement of proximal left anterior descending artery: Insight from arts II and arts I studies
    Fajadet, J
    Valgimigli, M
    Jukema, JW
    Kornowski, R
    Steg, G
    Betriu, A
    De Belder, M
    Pachinger, O
    Stoll, HP
    Serruys, PW
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (04) : 39B - 39B
  • [3] Three-year clinical outcome of percutaneous treatment of bifurcation lesions in multivessel coronary artery disease with the sirolimus-eluting stent: insights from the Arterial Revascularisation Therapies Study, part II (ARTS II)
    Routledge, Helen C.
    Lefevre, Thierry
    Colombo, Antonio
    Oldroyd, Keith G.
    Hamm, Christian W.
    Guagliumi, Giulio
    von Scheidt, Wolfgang
    Guetta, Victor
    Ruzyllo, Witold
    Wittebols, Kristel
    Goedhart, Dick M.
    Serruys, Patrick W.
    EUROINTERVENTION, 2009, 5 (02) : 190 - 196
  • [4] 5-Year Clinical Outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the Sirolimus-Eluting Stent in the Treatment of Patients With Multivessel De Novo Coronary Artery Lesions
    Serruys, Patrick W.
    Onuma, Yoshinobu
    Garg, Scot
    Vranckx, Pascal
    De Bruyne, Bernard
    Morice, Marie-Claude
    Colombo, Antonio
    Macaya, Carlos
    Richardt, Gert
    Fajadet, Jean
    Hamm, Christian
    Schuijer, Monique
    Rademaker, Tessa
    Wittebols, Kristel
    Stoll, Hans Peter
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (11) : 1093 - 1101
  • [5] The clinical outcome of percutaneous treatment of bifurcation lesions in multivessel coronary artery disease with the sirolimus-eluting stent:: insights from the Arterial Revascularization Therapies Study part II (ARTS II)
    Tsuchida, Keiichi
    Colombo, Antonio
    Lefevre, Thierry
    Oldroyd, Keith G.
    Guetta, Victor
    Guagliumi, Giulio
    von Scheidt, Wolfgang
    Ruzyllo, Witold
    Hamm, Christian W.
    Bressers, Marco
    Stoll, Hans-Peter
    Wittebols, Kristel
    Donohoe, Dennis J.
    Serruys, Patrick W.
    EUROPEAN HEART JOURNAL, 2007, 28 (04) : 433 - 442
  • [6] Arterial Revascularization Therapies Study: Part II of the sirolimus-eluting Bx VELOCITY balloon expandable stent in the treatment of patients with multivessel de novo coronary artery lesions
    Serruys, P
    Hamm, C
    Macaya, C
    De Bruyne, B
    Fajadet, J
    Colombo, A
    Richardt, G
    Dawkins, K
    Morice, MC
    AMERICAN JOURNAL OF CARDIOLOGY, 2004, 94 (6A): : 69E - 69E
  • [7] Efficacy of sirolimus-eluting stent in the treatment of patients with bifurcation lesions in multivessel coronary artery disease:: A substudy of the Arts II trial
    Colombo, A
    Tsuchida, K
    Lefèvre, T
    Serruys, P
    Oldroyd, K
    Guetta, V
    Guagliumi, G
    von Scheidt, W
    Ruzyllo, W
    Hamm, C
    CIRCULATION, 2005, 112 (17) : U481 - U482
  • [8] Revascularisation following Multivessel Sirolimus-eluting Stent Implantation: Indications and Long-term Follow-up From the Arterial Revascularisation Therapies Study Part 2 (ARTS-II)
    Kukreja, Neville
    Serruys, Patrick
    Ramcharitar, Steve
    Tanimoto, Shuzou
    Onuma, Yoshinobu
    de Bruyne, Bernard
    Colombo, Antonio
    Macaya, Carlos
    Richardt, Gert
    Fajadet, Jean
    Hamm, Christian
    Schuijer, Monique
    Pieters, Magdaleen
    Stoll, Hans-Peter
    CIRCULATION, 2008, 118 (18) : S804 - S804
  • [9] Comments on the article by Routledge et al "Three-year clinical outcome of percutaneous treatment of bifurcation lesions in multivessel coronary artery disease with the sirolimus-eluting stent: insights from the Arterial Revascularisation Therapies Study, part II (ARTS II)"
    Latib, Azeem
    Airoldi, Flavio
    EUROINTERVENTION, 2010, 5 (07) : 875 - 876
  • [10] Arterial revascularitation therapies study, part II. Sirolimus-eluting stents for the treatment of patients with multivessel de novo coronary artery lesions
    Macaya, C.
    EUROPEAN HEART JOURNAL, 2005, 26 : 410 - 410